Search research articles
Contact Us
Filters
Showing results (51-60 of 138) with videos related to
Page
of 14
Sort By:
The New England Journal of Medicine
|
November 9, 2012
Progression of RAS-mutant leukemia during RAF inhibitor treatment
Margaret K Callahan, Raajit Rampal, James J Harding, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 4, 2018
Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma
James J Harding, Ghaith Abu-Zeinah, Joanne F Chou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
Omid Hamid, Dana B Cardin, F Stephen Hodi, et al.
JCO Precision Oncology
|
July 12, 2021
Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations
Anna M Varghese, Juber Patel, Yelena Y Janjigian, et al.
Cancer Chemotherapy and Pharmacology
|
July 5, 2018
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies
James J Harding, Richard K Do, Imane El Dika, et al.
Liver Cancer
|
August 11, 2022
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
James J Harding, Ahmad Awada, Gael Roth, et al.
JCO Global Oncology
|
October 10, 2024
Clinical and Genomic Characterization of <i>ERBB2</i>-Altered Gallbladder Cancer: Exploring Differences Between an American and a Chilean Cohort
Sebastián Mondaca, Henry Walch, Santiago Sepúlveda, et al.
Current Oncology (Toronto, Ont.)
|
January 24, 2025
TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization
Ken Zhao, Anita Karimi, Luke Kelly, et al.
JAMA Ophthalmology
|
September 2, 2021
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy
Jasmine H Francis, James J Harding, Alison M Schram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
James J Harding, Melinda Telli, Pamela Munster, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 138) with videos related to
Sort By:
Page
of 14
The New England Journal of Medicine
|
November 9, 2012
Progression of RAS-mutant leukemia during RAF inhibitor treatment
Margaret K Callahan, Raajit Rampal, James J Harding, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 4, 2018
Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma
James J Harding, Ghaith Abu-Zeinah, Joanne F Chou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
Omid Hamid, Dana B Cardin, F Stephen Hodi, et al.
JCO Precision Oncology
|
July 12, 2021
Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations
Anna M Varghese, Juber Patel, Yelena Y Janjigian, et al.
Cancer Chemotherapy and Pharmacology
|
July 5, 2018
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies
James J Harding, Richard K Do, Imane El Dika, et al.
Liver Cancer
|
August 11, 2022
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
James J Harding, Ahmad Awada, Gael Roth, et al.
JCO Global Oncology
|
October 10, 2024
Clinical and Genomic Characterization of <i>ERBB2</i>-Altered Gallbladder Cancer: Exploring Differences Between an American and a Chilean Cohort
Sebastián Mondaca, Henry Walch, Santiago Sepúlveda, et al.
Current Oncology (Toronto, Ont.)
|
January 24, 2025
TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization
Ken Zhao, Anita Karimi, Luke Kelly, et al.
JAMA Ophthalmology
|
September 2, 2021
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy
Jasmine H Francis, James J Harding, Alison M Schram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
James J Harding, Melinda Telli, Pamela Munster, et al.
Page
of 14